SOHO 2023 | Challenges in treating patients with HL who relapse after autoSCT & novel therapies being explored
Stephen Ansell
• 8 Sep 2023
Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MN, discusses the challenges in treating patients with Hodgkin lymphoma (HL) who relapse after autologous stem cell transplantation (autoSCT). Prof. Ansell also highlights treatment approaches being explored for these patients, including novel cellular therapies, novel checkpoint inhibitors, and the role of allogeneic SCT (alloSCT). This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
